ZA200804509B - Methods for prediction and prognosis of cancer, and monitoring cancer therapy - Google Patents
Methods for prediction and prognosis of cancer, and monitoring cancer therapyInfo
- Publication number
- ZA200804509B ZA200804509B ZA200804509A ZA200804509A ZA200804509B ZA 200804509 B ZA200804509 B ZA 200804509B ZA 200804509 A ZA200804509 A ZA 200804509A ZA 200804509 A ZA200804509 A ZA 200804509A ZA 200804509 B ZA200804509 B ZA 200804509B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- prognosis
- prediction
- methods
- monitoring
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73585405P | 2005-11-14 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200804509B true ZA200804509B (en) | 2009-05-27 |
Family
ID=37814675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200804509A ZA200804509B (en) | 2005-11-14 | 2008-05-23 | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070178494A1 (en) |
| EP (1) | EP1963849A2 (en) |
| JP (1) | JP2009515553A (en) |
| KR (1) | KR20080073745A (en) |
| CN (1) | CN101454668A (en) |
| AU (1) | AU2006315592A1 (en) |
| BR (1) | BRPI0618597A2 (en) |
| CA (1) | CA2629860A1 (en) |
| MX (1) | MX2008006239A (en) |
| RU (1) | RU2008123406A (en) |
| WO (1) | WO2007059094A2 (en) |
| ZA (1) | ZA200804509B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Corporation | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| DK1478358T3 (en) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis |
| UY28213A1 (en) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS. |
| PT1626714E (en) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diaryl ureas for diseases mediated by pdgfr |
| ES2297490T3 (en) | 2003-07-23 | 2008-05-01 | Bayer Pharmaceuticals Corporation | OMEGA-CARBOXIARILDIFENILUREA FLUORO REPLACED FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS. |
| JP5304241B2 (en) | 2005-03-07 | 2013-10-02 | バイエル・ヘルスケア・エルエルシー | Pharmaceutical composition comprising omega-carboxyaryl substituted diphenylurea for the treatment of cancer |
| JP2009512860A (en) * | 2005-10-21 | 2009-03-26 | バイエル ヘルスケア エルエルシー | Cancer prediction and prognosis testing methods, and cancer treatment monitoring |
| RU2008121754A (en) * | 2005-11-02 | 2009-12-20 | БАЙЕР ХЕЛСКЕР ЛЛСи (US) | METHODS FOR FORECASTING AND PREDICTION OF CANCER AND MONITORING THERAPY OF CANCER DISEASES |
| EP2061906B1 (en) * | 2006-09-12 | 2011-08-31 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker |
| AR062927A1 (en) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4- ([[4- CHLORINE-3- (TRIFLUOROMETILE) PHENYL) CARBAMOIL] AMINO] -3- FLUOROPHENOXY) -N- METHYLPIRIDIN-2-MONOHIDRATED CARBOXAMIDE |
| WO2009094383A2 (en) * | 2008-01-25 | 2009-07-30 | Mayo Foundation For Medical Education And Research | Quantitation of lobular involution for breast cancer risk prediction |
| GB0814722D0 (en) * | 2008-08-12 | 2008-09-17 | Ge Healthcare Ltd | Treatment monitoring |
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| WO2010048304A2 (en) | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
| WO2011042829A1 (en) * | 2009-10-07 | 2011-04-14 | Koninklijke Philips Electronics N.V. | Method of evaluating toxicity level of a patient undergoing a cancer treatment |
| CN102053150B (en) * | 2009-10-30 | 2013-07-17 | 上海交通大学医学院附属瑞金医院 | Human osteosarcoma stem cell related antigen marker and application thereof |
| SG187013A1 (en) * | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| US20130131136A1 (en) * | 2010-08-02 | 2013-05-23 | Nicolae Ghinea | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor |
| PL2653546T3 (en) | 2010-12-13 | 2019-06-28 | Samsung Life Public Welfare Foundation | Marker for predicting stomach cancer prognosis and method for predicting stomach cancer prognosis |
| ES2609249T3 (en) * | 2011-01-11 | 2017-04-19 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Methods of predicting the outcome of a cancer in a patient analyzing gene expression |
| WO2013173384A1 (en) * | 2012-05-16 | 2013-11-21 | Dale Wong | Method and system for sorting biological samples |
| CN105308186A (en) * | 2013-03-15 | 2016-02-03 | 詹森药业有限公司 | Assay for predictive biomarkers |
| JP6489658B2 (en) * | 2013-04-25 | 2019-03-27 | シービーエス バイオサイエンス，カンパニー，リミテッド | Analytical method for increasing the sensitivity of molecular targeted therapy in hepatocellular carcinoma |
| RU2546035C1 (en) * | 2014-04-15 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Method for predicting metastases in patients with skin melanoma |
| RU2643761C1 (en) * | 2017-08-10 | 2018-02-05 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Method of calculation of forecast for early development of skin melanoma |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | Methods and compositions for detection and diagnosis of breast cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635421B1 (en) * | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
| US20030232400A1 (en) * | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
| WO2005009367A2 (en) * | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
| EP1744788A4 (en) * | 2004-03-19 | 2010-08-18 | Penn State Res Found | Combinatorial methods and compositions for treatment of melanoma |
-
2006
- 2006-11-14 CN CNA2006800505936A patent/CN101454668A/en active Pending
- 2006-11-14 MX MX2008006239A patent/MX2008006239A/en not_active Application Discontinuation
- 2006-11-14 RU RU2008123406/15A patent/RU2008123406A/en not_active Application Discontinuation
- 2006-11-14 KR KR1020087014220A patent/KR20080073745A/en not_active Application Discontinuation
- 2006-11-14 JP JP2008541268A patent/JP2009515553A/en active Pending
- 2006-11-14 WO PCT/US2006/044117 patent/WO2007059094A2/en active Application Filing
- 2006-11-14 BR BRPI0618597-5A patent/BRPI0618597A2/en not_active IP Right Cessation
- 2006-11-14 AU AU2006315592A patent/AU2006315592A1/en not_active Abandoned
- 2006-11-14 CA CA002629860A patent/CA2629860A1/en not_active Abandoned
- 2006-11-14 US US11/598,824 patent/US20070178494A1/en not_active Abandoned
- 2006-11-14 EP EP06837519A patent/EP1963849A2/en not_active Withdrawn
-
2008
- 2008-05-23 ZA ZA200804509A patent/ZA200804509B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070178494A1 (en) | 2007-08-02 |
| WO2007059094A3 (en) | 2008-01-24 |
| EP1963849A2 (en) | 2008-09-03 |
| RU2008123406A (en) | 2009-12-27 |
| CN101454668A (en) | 2009-06-10 |
| CA2629860A1 (en) | 2007-05-24 |
| MX2008006239A (en) | 2008-12-12 |
| BRPI0618597A2 (en) | 2011-09-06 |
| AU2006315592A1 (en) | 2007-05-24 |
| WO2007059094A2 (en) | 2007-05-24 |
| KR20080073745A (en) | 2008-08-11 |
| JP2009515553A (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190870A0 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| ZA200803430B (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| ZA200804509B (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| ZA200803516B (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| HK1151321A1 (en) | Method of diagnosing, classifying and treating endometrial cancer and precancer | |
| EP1922326A4 (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
| EP2147124A4 (en) | Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer | |
| EP2179037A4 (en) | Methods for diagnosis, prognosis and methods of treatment | |
| HK1116249A1 (en) | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer b7-h1 | |
| IL179059A0 (en) | Method of diagnosing prostate cancer | |
| EP1894131A4 (en) | Methods and systems for predicting cancer outcome | |
| HK1108284A1 (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
| GB0519405D0 (en) | Cancer therapy prognosis and target | |
| WO2007123722A3 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| HK1102501A1 (en) | Methods of oligosaccharide profiling for the detection of cancer | |
| EP1742654A4 (en) | Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer | |
| IL182813A0 (en) | Methods and systems for prognosis and treatment of solid tumors | |
| EP1909854A4 (en) | Method for treating cancer | |
| ZA200808669B (en) | Methods of treating, diagnosing or detecting cancer | |
| PT1611890E (en) | Methods for assessing and treating cancer | |
| EP1862804A4 (en) | Method for diagnosis of prostate cancer | |
| HK1117780A1 (en) | Compounds and methods for the treatment of cancer | |
| EP1977247A4 (en) | Methods for diagnosing and treating prostate cancer | |
| IL189377A0 (en) | Combinations comprising dmxaa for the treatment of cancer | |
| ZA200703482B (en) | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |